This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Two gout experts debated whether first-line urate-lowering therapy should consist of a xanthine oxidase inhibitor or should instead be tailored to the mechanism of a patient’s hyperuricemia.
Medscape Medical News